Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

FONTAN

Showing results (531-540 of 568) with videos related to

Pageof 57
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLaurent Garderet, Simona Iacobelli, Philippe Moreau, et al.
Scientific Reports|April 5, 2025
A transfer triage tool for COVID-19 mass critical care surgesYoucef Azeli, Silvia Solà-Muñoz, José Trenado, et al.
Blood|August 19, 2011
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaPhilippe Moreau, Herve Avet-Loiseau, Thierry Facon, et al.
Haematologica|February 26, 2026
Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphomaAnna Kuchnio, Danlin Yang, Nele Vloemans, et al.
Blood|October 31, 2015
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, et al.
Cancer Discovery|January 10, 2020
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in LymphomaPatrizia Mondello, Saber Tadros, Matt Teater, et al.
The Science of the Total Environment|November 22, 2023
Summary recommendations on "Analytical methods for substances in the Watch List under the Water Framework Directive"Robert Loos, Silwan Daouk, Dimitar Marinov, et al.
The International Journal of Angiology : Official Publication of the International College of Angiology, Inc|November 6, 2023
COVID-19-Associated Portal Vein Thrombosis Post-CholecystitisSara Guevara, Santiago J Miyara, Judith Aronsohn, et al.
Hypertension (Dallas, Tex. : 1979)|December 30, 2020
Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in SpainEnrique Rodilla, Maria Dolores López-Carmona, Xavi Cortes, et al.
Nature Materials|March 17, 2023
Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomasShivem B Shah, Christopher R Carlson, Kristine Lai, et al.
Pageof 57

Showing results (531-540 of 568) with videos related to

Sort By:
Pageof 57
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLaurent Garderet, Simona Iacobelli, Philippe Moreau, et al.
Scientific Reports|April 5, 2025
A transfer triage tool for COVID-19 mass critical care surgesYoucef Azeli, Silvia Solà-Muñoz, José Trenado, et al.
Blood|August 19, 2011
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaPhilippe Moreau, Herve Avet-Loiseau, Thierry Facon, et al.
Haematologica|February 26, 2026
Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphomaAnna Kuchnio, Danlin Yang, Nele Vloemans, et al.
Blood|October 31, 2015
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, et al.
Cancer Discovery|January 10, 2020
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in LymphomaPatrizia Mondello, Saber Tadros, Matt Teater, et al.
The Science of the Total Environment|November 22, 2023
Summary recommendations on "Analytical methods for substances in the Watch List under the Water Framework Directive"Robert Loos, Silwan Daouk, Dimitar Marinov, et al.
The International Journal of Angiology : Official Publication of the International College of Angiology, Inc|November 6, 2023
COVID-19-Associated Portal Vein Thrombosis Post-CholecystitisSara Guevara, Santiago J Miyara, Judith Aronsohn, et al.
Hypertension (Dallas, Tex. : 1979)|December 30, 2020
Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in SpainEnrique Rodilla, Maria Dolores López-Carmona, Xavi Cortes, et al.
Nature Materials|March 17, 2023
Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomasShivem B Shah, Christopher R Carlson, Kristine Lai, et al.
Pageof 57